Media - Ironwood Pharmaceuticals

Media

Home
Media

Meredith Kaya

Vice President, Investor Relations and Corporate Communications

617.374.5082

mkaya@ironwoodpharma.com

September 18, 2019

Ironwood Pharmaceuticals and AstraZeneca Amend LINZESS® (linaclotide) Collaboration in China

August 28, 2019

Ironwood Pharmaceuticals to Present at Upcoming September Investor Conferences

August 13, 2019

Ironwood Pharmaceuticals Announces Full Exercise of Convertible Notes Over-Allotment

August 13, 2019

Ironwood Pharmaceuticals and Alnylam Pharmaceuticals Enter U.S. GI Disease Education and Promotional Agreement for Alnylam’s Givosiran in Acute Hepatic Porphyria (AHP)

August 8, 2019

Ironwood Pharmaceuticals Announces Pricing of Upsized $350 Million Convertible Senior Notes Offering

August 6, 2019

Ironwood Pharmaceuticals Announced Proposed Offering of $330 Million of Convertible Senior Notes

July 30, 2019

Ironwood Pharmaceuticals Reports Second Quarter 2019 Results

July 18, 2019

Ironwood Pharmaceuticals to Host Second Quarter 2019 Investor Update Call

June 18, 2019

Ironwood and Allergan Report Positive Topline Data from Phase IIIb Trial of LINZESS® (linaclotide) in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)

June 13, 2019

Ironwood Pharmaceuticals to Establish New Headquarters in Downtown Boston

June 3, 2019

Ironwood Pharmaceuticals and Allergan Initiate Patient Dosing in Phase II Clinical Trial of MD-7246 in Patients with Abdominal Pain Associated with IBS-D

May 9, 2019

Ironwood Pharmaceuticals to Highlight IW-3718 and Linaclotide Data at Digestive Disease Week® 2019

May 7, 2019

Ironwood Pharmaceuticals to Present at the 2019 Bank of America Merrill Lynch Healthcare Conference

May 2, 2019

Ironwood Pharmaceuticals Reports First Quarter 2019 Results; Announces Positive 2019 Adjusted EBITDA from Continuing Operations Guidance

April 18, 2019

Ironwood Pharmaceuticals to Host First Quarter 2019 Investor Update Call

April 16, 2019

Ironwood Pharmaceuticals Announces Adjustment of Conversion Rate for its 2.25% Convertible Senior Notes due 2020

April 1, 2019

Ironwood Pharmaceuticals Completes Separation of Cyclerion Therapeutics and Becomes a Gastrointestinal (GI)-focused Healthcare Company

March 14, 2019

Ironwood Announces Effectiveness of Cyclerion Form 10 Registration Statement

March 7, 2019

Ironwood Pharmaceuticals to Present at Barclays Global Healthcare Conference

March 4, 2019

Ironwood Pharmaceuticals to Present at Cowen Health Care Conference

Copyright © 2019, Ironwood Pharmaceuticals, Inc. All Rights Reserved

LINZESS®, CONSTELLA®, IRONWOOD® and their associated logos are trademarks of Ironwood Pharmaceuticals, Inc. Any other trademarks referred to herein are the property of their respective owners. All rights reserved.